H
Hui-fang Zhao
Researcher at University of Science and Technology Beijing
Publications - 5
Citations - 65
Hui-fang Zhao is an academic researcher from University of Science and Technology Beijing. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 2, co-authored 2 publications receiving 26 citations.
Papers
More filters
Journal ArticleDOI
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.
Yuankai Shi,Gongyan Chen,Xinkang Wang,Yunpeng Liu,Lin Wu,Yanrong Hao,Chunling Liu,Shuyang Zhu,Xiaodong Zhang,Yuping Li,Jiwei Liu,Lejie Cao,Ying Cheng,Hui-fang Zhao,Shucai Zhang,Aimin Zang,Jiuwei Cui,Jian Feng,Nong Yang,Fei Liu,Yong Jiang,Chuan Gu +21 more
TL;DR: Furmonertinib (AST2818) is an irreversible, selective, third-generation EGFR tyrosine-kinase inhibitor as discussed by the authors , which is a new potential treatment option for this population.
Journal ArticleDOI
Lysosome destabilization by cytosolic extracts, putative involvement of Ca2+/phospholipase C
TL;DR: The results indicate that the cytosol induced an osmotic shock to the lysosomes and an influx of water into the organelle, and suggests that the destabilization effect of cytOSol on the lYSosomes is Ca2+‐dependent.
Journal ArticleDOI
Mechanism of cytosol phospholipase C and sphingomyelinase-induced lysosome destabilization.
TL;DR: The results suggest that cytosolic phospholipase C and sphingomyelinase may be responsible for the alterations in lysosomal stability by increasing the ion permeability.
Journal ArticleDOI
Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR mutated non-small cell lung cancer: results from the FURLONG study.
Yuankai Shi,Gongyan Chen,Xinkang Wang,Yunpeng Liu,Lin Wu,Yanrong Hao,Chunling Liu,Shuyang Zhu,Xiaodong Zhang,Yuping Li,Jiwei Liu,Lejie Cao,Ying Chen,Hui-fang Zhao,Shucai Zhang,Aimin Zang,Jiuwei Cui,Jian Feng,Nong Yang,Meilin Liu,Yong Jiang,Chuan Gu +21 more
TL;DR: In this article , the authors reported the CNS efficacy of furmonertinib compared with gefitinib in untreated EGFR-sensitizing mutation-positive NSCLC from the FURLONG study.
Journal ArticleDOI
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies
Xingsheng Hu,Shucai Zhang,Zhiyong Ma,Jifeng Feng,Lin Wu,Dongqing Lv,Jianying Zhou,Xiaodong Zhang,Li Liu,Qitao Yu,Wangjun Liao,Yiping Zhang,Xinkang Wang,Ying Cheng,Hong-rui Niu,Ziping Wang,Dong Wang,Cheng Huang,Chunling Liu,Hui-fang Zhao,Jian Feng,Jingzhang Li,Kejing Ying,Nong Yang,Shukui Qin,J. Hu,Meilin Liu,Yong Jiang,Nan Ge,Yuankai Shi +29 more
TL;DR: In this paper , the authors report the pooled central nervous system (CNS) efficacy data of furmonertinib in patients with EGFR T790M mutated non-small cell lung cancer (NSCLC) from two phase 2 studies.